



Figure S1 Representative radiologic findings of pulmonary lymphangitic carcinomatosis (PLC), classified as cLy1 (A), cLy2 (B), cLy3 (C,D), and cLy4 (E,F). (A) The primary tumor (black arrow) is in right upper lobe and PLC (white arrow) is confined to area around the primary tumor. (B) The primary tumor (black arrow) is in right upper lobe and PLC (white arrow) is at a distance from the primary tumor but confined to the same lobe. (C,D) The primary tumor (black arrow) is in right lower lobe, and PLC (white arrow) extends to the right middle lobe. (E,F) The primary tumor (black arrow) is in the left lower lobe, and PLC (white arrow) extends to the left upper, right lower, and right upper lobes.

Table S1 Summary of palliative chemotherapy which study subjects received

Characteristic	PLC (n=37)	IM (n=97)
Cytotoxic chemotherapy	31	75
Cisplatin + pemetrexed	10	34
Cisplatin + gemcitabine	9	20
Cisplatin + docetaxel	6	4
Cisplatin + paclitaxel	2	4
Carboplatin + gemcitabine	2	12
Carboplatin + paclitaxel	2	1
EGFR-TKI	6	20
Gefitinib	3	15
Erlotinib	2	4
Afatinib	1	1
ALK-TKI	0	2
Alectinib	0	2

Data are presented as number. PLC, pulmonary lymphangitic carcinomatosis; IM, intrapulmonary metastases; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; ALK-TKI, anaplastic lymphoma kinase-tyrosine kinase inhibitor.

Table S2 Characteristics of patients with PLC who received surgical treatment

Characteristic	Patients (n=39)
Age, years	62 (55–66)
Sex, male	26 (67)
Smoking status	
Current smoker	14 (36)
Former smoker	15 (39)
Never	10 (26)
Neoadjuvant treatment	
No	5 (15)
Yes	28 (85)
Tumor histology	
Adenocarcinoma	25 (64)
Squamous cell carcinoma	13 (33)
Other NSCLC	1 (3)
Lymphatic invasion in surgical specimens	39 (100)
T stage*	
pT1	12 (31)
pT2	19 (49)
pT3	8 (20)
pT4	0
Nodal stage*	
pN0	10 (26)
pN1	6 (15)
pN2	22 (56)
pN3	1 (3)
Tumor location	
Right upper lobe	10 (26)
Right middle lobe	3 (8)
Right lower lobe	10 (26)
Left upper lobe	12 (30)
Left lower lobe	4 (10)
Extent of surgery	
Bilobectomy	3 (8)
Lobectomy	36 (92)
Adjuvant treatment	
Concurrent chemoradiation therapy	7 (18)
Chemotherapy	9 (23)
Radiotherapy	12 (31)
No adjuvant treatment	11 (28)
Prognosis	
No evidence of progression	13 (33)
Local relapse	12 (31)
Lung	7 (18)
Lymph node	5 (13)
Distant metastasis	14 (36)
Deaths	20 (51)

Data are presented as medians (interquartile ranges) or n (%). *, 8th edition of TNM classification for lung cancer. PLC, pulmonary lymphangitic carcinomatosis; IM, intrapulmonary metastases; NSCLC, non-small cell lung cancer.